Peptide Encyclopaedia
IGF-1 LR3
Research / investigational listing only. This compound is not available for consumer purchase from Cellular Sequence and must not be confused with shop products.
Research / investigational compoundThis compound does not have an established approved therapeutic dosing schedule. Doses below describe those reported in published scientific research and should not be interpreted as a treatment recommendation.
At-a-glance profile
- Classification
- Long-acting IGF-1 analogue (research only)
- Approval status
- Research only · Not approved for human use
- Research status
- Investigational / reference listing.
- Molecular formula
- Insufficient reliable evidence identified.
- Molecular weight
- Insufficient reliable evidence identified.
- Sequence
- IGF-1 with Arg3 substitution and N-terminal extension (LR3).
- Primary biological target
- Insufficient reliable evidence identified.
- Half-life
- Insufficient reliable evidence identified.
- Routes investigated
- Insufficient reliable evidence identified.
- Human evidence level
- D — Primarily animal / preclinical evidence
What is it?
Potent growth-factor analogue. Not approved for physique or anti-ageing. Not sold. High medical risk.
Mechanism of action
IGF-1 receptor agonism with altered binding proteins.
Would affect growth, glucose and potentially tumours — exactly why unregulated use is inappropriate.
What is it being studied for?
- Experimental growth-factor biology
Investigational findings are not proven clinical benefits unless an authority has labelled that indication.
Evidence level
Overall human evidence grade: D · Primarily animal / preclinical evidence
Human research
Not a registered lifestyle medicine.
Preclinical research
Animal, cell and in-vitro findings are listed separately from human effects.
IGF-1 receptor biology is real and serious.
Doses reported in published research
This section does not provide personalised medical dosing. Values are those reported in papers or protocols. Animal mg/kg doses are not converted to human doses.
Doses reported in human studies
Insufficient reliable evidence identified.
Preclinical / animal study dosing
Insufficient reliable evidence identified.
Pharmacokinetics
Reliable human pharmacokinetic data were not identified for this encyclopaedia entry, or are limited to product information for approved presentations.
Safety
Hypoglycaemia, oedema, theoretical tumour-promotion. WADA prohibited.
Unknowns. Absence of a published harm signal is not evidence of safety.
Contraindications. Not for human use. Malignancy.
Regulatory status
Not approved for these grey-market uses.
Educational warning entry.
Citations
[1] Encyclopaedia note
Encyclopaedia note
For educational and research reference only. This page summarises published scientific literature and does not constitute medical advice, prescribing information or a recommendation to use an investigational compound. Research doses shown describe doses reported in published studies and are not personalised dosing instructions.
Last reviewed 2026-09-13. Research areas: Performance · Compare peptides